Zobrazeno 1 - 10
of 35
pro vyhledávání: '"Maria Jose Mendez"'
Autor:
Javier Puente, Urbano Anido, Miguel Ángel Climent, Enrique Gonzalez-Billalabeitia, Nuria Lainez, Julio Lambea, José Pablo Maroto, Maria Jose Mendez-Vidal, Álvaro Montesa, Angel Rodriguez, Curro Zambrana, Aránzazu González-del-Alba
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Objective: Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT
Externí odkaz:
https://doaj.org/article/75ff313d187749adb79d84a4a14b63f7
Autor:
Cristina Suárez, James M.G. Larkin, Poulam Patel, Begoña P. Valderrama, Alejo Rodriguez-Vida, Hilary Glen, Fiona Thistlethwaite, Christy Ralph, Gopalakrishnan Srinivasan, Maria Jose Mendez-Vidal, Ryan Hartmaier, Aleksandra Markovets, Aaron Prendergast, Bernadett Szabados, Kelly Mousa, Thomas Powles
Publikováno v:
Journal of Clinical Oncology. 41:2493-2502
PURPOSE Metastatic papillary renal cancer (PRC) has poor outcomes, and new treatments are required. There is a strong rationale for investigating mesenchymal epithelial transition receptor (MET) and programmed cell death ligand-1 (PD-L1) inhibition i
Autor:
Bernadett Szabados, Mark Kockx, Zoe June Assaf, Pieter-Jan van Dam, Alejo Rodriguez-Vida, Ignacio Duran, Simon J. Crabb, Michiel S. Van Der Heijden, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, Maria Jose Mendez, Cristina Suarez, Mark Linch, Aaron Prendergast, Charlotte Tyson, Diana Stanoeva, Sofie Daelemans, Miche Rombouts, Sanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Shruti Sharma, Alexey Aleshin, Romain Banchereau, Daniel Castellano, Thomas Powles
Publikováno v:
European urology
[Background] Neoadjuvant immunotherapies hold promise in muscle-invasive bladder cancer (MIBC).
[Objective] To report on 2-yr disease-free (DFS) and overall (OS) survival including novel tissue-based biomarkers and circulating tumor DNA (ctDNA)
[Objective] To report on 2-yr disease-free (DFS) and overall (OS) survival including novel tissue-based biomarkers and circulating tumor DNA (ctDNA)
Autor:
Javier Puente, Alvaro Pinto, Maria Jose Mendez Vidal, Xavier Garcia del Muro, Pablo Maroto-Rey, Sergio Vazquez-Estevez, Raquel Luque, Urbano Anido, Torsten Strunz-McKendry, Anil Upadhyay, Jose Montes, Aurora Ortiz Nuñez, Judit González Portela, Daniel Castellano
Publikováno v:
Journal of Clinical Oncology. 41:463-463
463 Background: Real-world evidence on la/mUC management in Europe is limited. This study describes patient (pt) characteristics, treatment patterns, survival, and HCRU for pts with la/mUC in Spain. Methods: A retrospective chart review was conducted
Autor:
Francesca Jackson-Spence, Charlotte Ackerman, Bernadett Szabados, Charlotte Toms, Agne Jovaisaite, Rachel Gunnell, Cristina Suárez, James Larkin, Poulam Patel, Begoña Pérez Valderrama, Alejo Rodriguez-Vida, Hilary Glen, Fiona C. Thistlethwaite, Christy Ralph, Gopalakrishnan Srinivasan, Maria Jose Mendez-Vidal, Aleksandra Markovets, Ryan James Hartmaier, Thomas Powles
Publikováno v:
Journal of Clinical Oncology. 41:725-725
725 Background: The characterisation of DNA alternations in papillary renal cancer (PRC) is unclear. The CALYPSO trial (NCT02819596) prospectively evaluated combination therapy of savolitinib (MET inhibitor) and durvalumab (PD-L1 inhibitor) in PRC. T
Autor:
Maria Jose Juan FITA, Urbano Anido Herranz, Maria Jose Mendez Vidal, Regina Gironés, Begoña Mellado-Gonzalez, José Manuel Sepulveda Sánchez, Carlos Alvarez-Fernandez, Miguel Ángel Climent, Lucia Heras
Publikováno v:
Journal of Clinical Oncology. 41:168-168
168 Background: Prostate cancer is the second most common cancer in men. A number of important systemic therapies have been developed to treat mCRPC and now comprise the current therapeutic landscape. Docetaxel became the first systemic therapy to im
Autor:
Maria Jose Mendez, Luis Páez
Publikováno v:
Revista Amazônida: Revista do Programa de Pós-Graduação em Educação da Universidade Federal do Amazonas. 1:319-350
Este artículo tiene como principal objetivo la caracterización y el análisis, ordenado en tiempo y espacio, del proceso de sistematización de la escolarización en la provincia de Tierra del Fuego AeIAS, Argentina, entre 1884, año de la fundaci
Autor:
Robert Motzer, Camillo Porta, Boris Alekseev, Sun Young Rha, Toni K Choueiri, Maria Jose Mendez-Vidal, Sung-Hoo Hong, Anil Kapoor, Jeffrey C Goh, Masatoshi Eto, Lee Bennett, Jinyi Wang, Jie Janice Pan, Todd L Saretsky, Rodolfo F Perini, Cixin Steven He, Kalgi Mody, David Cella
Publikováno v:
Lancet Oncol
BACKGROUND: Results from the phase 3 CLEAR study showed that lenvatinib plus pembrolizumab improved progression-free survival and overall survival compared with sunitinib in patients with advanced renal cell carcinoma. We aimed to assess the health-r
Autor:
Pablo Maroto, Begoña Mellado, Teresa de Portugal, Mariona Figols, Sonia Maciá, Xavier Maldonado, Palmira Foro, Enrique Gallardo, Ramon Aldabo, Joan Carles, José Sánchez García, Raquel Luque, Teresa Bonfill, Joaquim Bellmunt, Montserrat Domenech, Maria Jose Mendez, Cristina Suárez, Albert Font, Rafael Morales-Barrera, María Isabel Sáez
Publikováno v:
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
International Journal of Radiation Oncology Biology Physics
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
International Journal of Radiation Oncology Biology Physics
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Purpose: Docetaxel improves survival in patients with metastatic prostate cancer. This randomized phase 2 trial aimed to assess the activity of weekly docetaxel with radiation therapy (RT) plus androgen deprivation in patients with high-risk localize
Autor:
Thomas Powles, Maria Jose Mendez-Vidal, Alejo Rodriguez-Vida, Begoña Pérez-Valderrama, Emilio Esteban, Fiona Thistlethwaite, Poulam M. Patel, Urbano Anido Herranz, Gopalakrishnan Srinivasan, Abdel Hamid, James Larkin, Christy Ralph, Stefan N. Symeonides, Javier Puente, Ryan Hartmaier, Aleksandra Markovets, Aaron Prendergast, Kelly Mousa, Cristina Suarez
Publikováno v:
Journal of Clinical Oncology. 40:LBA4503-LBA4503
LBA4503 Background: New drug combinations are required in advanced clear cell renal cancer (RCC). These potentially include MET inhibition with savolitinib (S) or CTLA-4 inhibition with tremelimumab (T). In this study these agents were given alone or